- Home
- IDR vs TLSI Comparison
IDR vs TLSI Comparison
Compare IDR & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- TLSI
- Stock Information
- Founded
- IDR 1996
- TLSI 2010
- Country
- IDR United States
- TLSI United States
- Employees
- IDR N/A
- TLSI N/A
- Industry
- IDR Precious Metals
- TLSI Medical Specialities
- Sector
- IDR Basic Materials
- TLSI Health Care
- Exchange
- IDR Nasdaq
- TLSI Nasdaq
- Market Cap
- IDR 142.7M
- TLSI 158.0M
- IPO Year
- IDR N/A
- TLSI N/A
- Fundamental
- Price
- IDR $12.66
- TLSI $5.77
- Analyst Decision
- IDR Strong Buy
- TLSI Strong Buy
- Analyst Count
- IDR 1
- TLSI 6
- Target Price
- IDR $14.00
- TLSI $11.75
- AVG Volume (30 Days)
- IDR 177.8K
- TLSI 39.3K
- Earning Date
- IDR 03-24-2025
- TLSI 03-27-2025
- Dividend Yield
- IDR N/A
- TLSI N/A
- EPS Growth
- IDR 344.27
- TLSI N/A
- EPS
- IDR 0.52
- TLSI N/A
- Revenue
- IDR $21,955,008.00
- TLSI $26,891,000.00
- Revenue This Year
- IDR $86.37
- TLSI $61.29
- Revenue Next Year
- IDR $11.11
- TLSI $53.21
- P/E Ratio
- IDR $25.24
- TLSI N/A
- Revenue Growth
- IDR 64.93
- TLSI 67.90
- 52 Week Low
- IDR $6.91
- TLSI $3.50
- 52 Week High
- IDR $18.35
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- IDR 48.80
- TLSI 68.94
- Support Level
- IDR $12.82
- TLSI $5.40
- Resistance Level
- IDR $13.45
- TLSI $5.82
- Average True Range (ATR)
- IDR 0.67
- TLSI 0.24
- MACD
- IDR -0.13
- TLSI 0.01
- Stochastic Oscillator
- IDR 1.08
- TLSI 89.19
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.